Media headlines about Zynerba Pharmaceuticals (NASDAQ:ZYNE) have trended somewhat negative on Tuesday, according to Accern. The research firm ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Zynerba Pharmaceuticals earned a news impact score of -0.03 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 47.8964208679346 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
NASDAQ:ZYNE traded up $0.03 during trading hours on Tuesday, reaching $11.32. 192,574 shares of the company’s stock were exchanged, compared to its average volume of 288,205. The stock has a market capitalization of $152.29 million, a price-to-earnings ratio of -4.56 and a beta of 4.86. Zynerba Pharmaceuticals has a 12 month low of $5.42 and a 12 month high of $20.73.
Zynerba Pharmaceuticals (NASDAQ:ZYNE) last issued its quarterly earnings results on Tuesday, May 8th. The company reported ($0.91) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.68) by ($0.23). research analysts predict that Zynerba Pharmaceuticals will post -3.03 earnings per share for the current fiscal year.
ZYNE has been the subject of a number of research reports. ValuEngine cut shares of Zynerba Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Monday, April 2nd. Zacks Investment Research upgraded shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating and set a $12.00 target price for the company in a report on Thursday, March 15th. HC Wainwright set a $23.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, March 6th. Seaport Global Securities restated a “buy” rating on shares of Zynerba Pharmaceuticals in a report on Tuesday, March 13th. Finally, Cantor Fitzgerald set a $20.00 target price on shares of Zynerba Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, April 25th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus target price of $17.86.
In other news, major shareholder Michael Rapp purchased 15,000 shares of Zynerba Pharmaceuticals stock in a transaction that occurred on Wednesday, May 2nd. The stock was acquired at an average price of $10.46 per share, for a total transaction of $156,900.00. The purchase was disclosed in a filing with the SEC, which is accessible through this link. In the last 90 days, insiders purchased 30,885 shares of company stock valued at $311,198. 12.67% of the stock is owned by insiders.
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc operates as a clinical stage specialty pharmaceutical company. The company focuses on developing and commercializing pharmaceutically-produced transdermal cannabinoid treatments for rare or near-rare neuropsychiatric disorders. Its product candidates include ZYN002, which completed Phase II clinical trial for pediatric and adolescent patients with fragile X syndrome, pediatric and adolescent patients with developmental and epileptic encephalopathies, and adult patients with refractory epileptic focal seizures; and ZYN001 that is in Phase I clinical trial to treat Tourette syndrome.
Receive News & Ratings for Zynerba Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.